Increased potency of vanadium using organic ligands

  • John H. McNeill
  • Violet G. Yuen
  • Soter Dai
  • Chris Orvig
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 16)


The in vivo glucose lowering effect of orally administered inorganic vanadium compounds in diabetes was first reported in our laboratory in 1985. While both vanadate and vanadyl forms of vanadium are orally active, they are still not well absorbed. We have synthesized several organic vanadium compounds and one compound, bis(maltolato)oxovanadium(IV) or BMOV, has been extensively investigated. BMOV proved effective in lowering plasma glucose and lipids in STZ-diabetic rats when administered in drinking water over a 25 week period. The maintenance dose (0.18 mmol/kg/day) was approximately 50% of that required for vanadyl sulfate (VS). Secondary complications of diabetes were prevented by BMOV and no marked toxicity was noted. Oral gavage of STZ-diabetic rats with BMOV also reduced blood glucose levels. The ED50 for BMOV was 0.5 mmol/kg, while for VS the estimated ED50 was 0.9 mmol/kg. BMOV was also effective by the intraperitoneal route in STZ-diabetic rats. The ED50 was 0.08 mmol/kg compared to 0.22 mmol/kg for VS. Some animals treated p.o. or i.p. remained euglycemic for up to 14 weeks. An i.v. infusion of BMOV of 0.05 mmol/kg over a 30 min period reduced plasma glucose levels by 50% while VS was not effective.

Key words

Vanadium diabetes insulin-mimetic hypertension 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Willsky GR: Vanadium in the biosphere. In: N. Dennis Chaasteen (ed.). Vanadium in biological systems. Kluwer Academic Publishers, Dordrecht, 1990, pp 124Google Scholar
  2. 2.
    Cantley LC Jr, Josephson L, Warner R, Yanagisawa M, Lechene C, Guidotti G: Vanadate is a potent (Na,K)-ATPase inhibitor found in ATP derived from muscle. Journal of Biological Chemistry 252 (21): 7421–7423, 1977PubMedGoogle Scholar
  3. 3.
    Nechay BR: Mechanisma of action of vanadium. Annual Review Pharmacology and Toxicology 24: 501–524, 1984CrossRefGoogle Scholar
  4. 4.
    Jackson T, SalhanickAI, Sparks JD, Sparks CE, Bolognino M,Amatrude JM: Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes 37: 1234–1240, 1988PubMedCrossRefGoogle Scholar
  5. 5.
    Duckworth WC, Solomon SS, Liepnieks J, Hamel FG, Hand S, Peavy DE: Insulin-like effects of vanadate in isolated rat adipocytes. Endocrinology 122: 2285–2289, 1988PubMedCrossRefGoogle Scholar
  6. 6.
    Shechter Y, Karlish SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 284: 556–558, 1980PubMedCrossRefGoogle Scholar
  7. 7.
    Tamura S, Brown TA, Whipple JH, Fujita-Yamaguchi Y, Dubler RE, Chemg K, Larner J: A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. Journal of Biological Chemistry 259 (10): 6650–6658, 1984.PubMedGoogle Scholar
  8. 8.
    Tamura S, Brown TA, Dubler RE, Larner J: Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochem Biophys Research Communication 113: 8042, 1983Google Scholar
  9. 9.
    Klarlund JK: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosineinproteins. Cell 4: 707–711, 1985CrossRefGoogle Scholar
  10. 10.
    Mooney RA, Bordwell KL, Luhowsky S, Casnellie JE: The insulin-like effect of vanadate on lipolysis in rat adiposytes is not accompanied by an insulin-like effect on tyrosine phosphorylation. Endocrinology 124: 422–429, 1989PubMedCrossRefGoogle Scholar
  11. 11.
    Bernier M, Laird DM, Lane MD: Effect of vanadate on the cellular accumulation of ppl5, an apparent product of insulin receptor tyrosine kinase activity. Journal of Biological Chemistry 263 (27): 13626–13634, 1988PubMedGoogle Scholar
  12. 12.
    Fantus EG, Kadota S, Deragon G, Foster B, Posner B: Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipbocytes via activation of the insulin receptor tyrosine kinase. Biochemistry 28: 8864–8871, 1989PubMedCrossRefGoogle Scholar
  13. 13.
    Junod A, Lambert AE, Stauffacher W, RenoldAE: Diabetogenic action of streptozotocin: relationship of dose to metabolic response. Jounal of Clinical Investigation 48: 2129–2139, 1969CrossRefGoogle Scholar
  14. 14.
    Kaufmann F, Rodriguez RR: Subtotal pancreatectomy in five different rat strains: incidence and course of development of diabetes. Diabetologia 27: 38–43, 1984PubMedCrossRefGoogle Scholar
  15. 15.
    Nakhooda AF, Like AA, Chappel CI, Murray FT, Marilss EB: The spontaneously diabetic Wistar rat; metabolic and morphologic studies. Diabetes 26: 100–112, 1977PubMedCrossRefGoogle Scholar
  16. 16.
    Nakhooda AF, Like AA, Marliss EB: Diabetes mellitus in the ‘BB’ Wistar rat. In: E.J. Andrews, B.C. Ward and N.H. Altman (eds). Spontaneous Animal Models of Human Disease. Volume I, Academic Press, Toronto, 1979, pp 131–136Google Scholar
  17. 17.
    Ramanadham S, Mongold JJ, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in the treatment of diabetes mellitus in rats. American Journal of Physiology 257: H904–H911, 1989aPubMedGoogle Scholar
  18. 18.
    Rossetti L, Giaccari A, Klein-Robbenhaar E, Vogel LR: Insulinomimetic properties of trace elements and characterization of their in vivo mode of action. Diabetes 39: 1243–1250, 1990PubMedCrossRefGoogle Scholar
  19. 19.
    Battell ML, Yuen VG, McNeill JH: Treatment of BB rats with vanadyl sulfate. Pharmacological Communications 1 (4): 291–301, 1992Google Scholar
  20. 20.
    Cam MC, Pederson RA, Brownsey RW, McNeill JH: Long-term effectiveness of oral vanadyl sulfate in streptozotocin-diabetic rats. Diabetologia 36: 218–224, 1993aPubMedCrossRefGoogle Scholar
  21. 21.
    Brichard SM, Pattier AM, Henquin JC: Long term improvement of glucose homeostatis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 126: 2510–2516, 1989CrossRefGoogle Scholar
  22. 22.
    Brichard SM, Bailey CJ, Henquin JC: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326–1332, 1990PubMedCrossRefGoogle Scholar
  23. 23.
    Blondel O, Simon J, Shevalier B, Portha B: Impaired insulin action but normal insulin receptor activity in diabetic rat liver: effect of vanadate. American Journal of Physiology 258 (Endocrinol Metab 21): E459–E467, 1990PubMedGoogle Scholar
  24. 24.
    Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474–1477, 1985PubMedCrossRefGoogle Scholar
  25. 25.
    Roschin AV, Ordizhonidze EK, Shalganova IV: Vanadium-toxicity, metabolism, carrier state. Jour Hyg Epid Microbiol Immunol 24: 377–383, 1980Google Scholar
  26. 26.
    Ramanadham S, Brownsey RW, Cros GH, Mongold JJ, McNeill JH: Sustained prevention of myocardial abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 38: 1022–1028, 1989bPubMedCrossRefGoogle Scholar
  27. 27.
    Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH: Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats. Diabetes 38: 1390–1395, 1989PubMedCrossRefGoogle Scholar
  28. 28.
    Cam MC, Faun J, McNeill JH: Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin diabetic rats. Metabolism 1994 (in press)Google Scholar
  29. 29.
    Dai S, Thompson KH, McNeill JH: One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate. Pharmacology and Toxicology 74:101–109, 1994aPubMedCrossRefGoogle Scholar
  30. 30.
    Dai S, McNeill JH: One-year treatment of non-diabetic and streptozotocin-diabetic-rats with vanadyl sulphate did not alter blood pressure or haematological indices. Pharmacology and Toxicology 74: 110–115, 1994bPubMedCrossRefGoogle Scholar
  31. 31.
    Rocchini AP: Is insulin resistance in hypertension a generalized phenomena? In: U. Smith, N.E. Bruun, T. Hedner and B. Hokfelt (eds). Hypertension is an insulin resistant disorder: genetic factors and cellular mechanisms. Excerpta Medica, 1992, pp 213–225Google Scholar
  32. 32.
    Reaven GM, Chang H: Relationship between blood pressure, plasma insulin and triglyceride concentration and insulin action in spontaneously hypertensive and Wistar Kyoto rats. American Journal of Hypertension 4: 34–38, 1991PubMedGoogle Scholar
  33. 33.
    Reaven GM, Chang H, Hoffman BB, Azhar S: Resistance to insulin stimulated glucose uptake in adipocytes isolated from spontaneously hypertensive rats. Diabetes 38: 1155–1160, 1989PubMedCrossRefGoogle Scholar
  34. 34.
    Buchanan TA, Youn JH, Campese VM, Sipos GF: Enhanced glucose tolerance in spontaneously hypertensive rats: pancreatic β-cell hyperfunction with normal insulin sensitivity. Diabetes 41: 872–878, 1992PubMedCrossRefGoogle Scholar
  35. 35.
    Bhanot S, McNeill JH: Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension 24: 625–632, 1994aPubMedGoogle Scholar
  36. 36.
    Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose induced insulin resistance and hypertension in rats. Hypertension 10: 512–516, 1987PubMedGoogle Scholar
  37. 37.
    Bhanot S, McNeill JH, Bryer-Ash M: Vanadyl sulfate prevents fuctose-induced hyperinsulinemia and hypertension in rats. Hypertension 23: 308–312, 1994bPubMedGoogle Scholar
  38. 38.
    Conklin AW, Skinner CS, Feltin TL, Sanders CL: Clearance and distribution of intratracheally instilled vanadium-48 compounds in the rat. Toxicological Letters 11: 199–203, 1982CrossRefGoogle Scholar
  39. 39.
    Underwood EJ: Vanadium In: Trace elements in human and animal nutrition. Academic Press, New York, 1977, pp 388–397Google Scholar
  40. 40.
    Cam MC, Cros GH, Serrano JJ, Lazaro R, McNeill JH: In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes. Diabetes Research and Clinical Practice 20: 111–121, 1993bPubMedCrossRefGoogle Scholar
  41. 41.
    McNeill JH, Yuen VG, Hoveyda HR, Orvig C: Bis(maltolato) oxovanadium(IV) is a potent insulin mimic. Journal of Medicinal Chemistry 35 (8): 1489–1491, 1992PubMedCrossRefGoogle Scholar
  42. 42.
    Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Canadian Journal of Physiology and Pharmacology 71: 270–276, 1993aPubMedCrossRefGoogle Scholar
  43. 43.
    Dai S, Yuen VG, Orvig C, McNeill JH: Prevention of diabetes-induced pathology in STZ-diabetic rats by bis(maltolato)oxovanadium(JV). Pharmacological Communications 3 (4): 311–321, 1993Google Scholar
  44. 44.
    Yuen VG, Orvig C, McNeill JH: Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Canadian Journal of Physiology and Pharmacology 71:263–269, 1993bPubMedCrossRefGoogle Scholar
  45. 45.
    Yuen VG, Orvig C, McNeill JH: Comparison of the glucose lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Canadian Journal of Physiology and Pharmacology 73: 55–64, 1995PubMedCrossRefGoogle Scholar
  46. 46.
    Bhanot S, Bryer-Ash M, Cheung A, McNeill JH: Bis(maltolato)oxo-vanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes 43: 857–861, 1994cPubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • John H. McNeill
    • 1
  • Violet G. Yuen
    • 1
  • Soter Dai
    • 1
  • Chris Orvig
    • 2
  1. 1.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada
  2. 2.Department of ChemistryUniversity of British ColumbiaVancouverCanada

Personalised recommendations